The U.S. Interventional Oncology Market was valued at USD 998.4 Million in 2024, and is projected to reach USD 1.59 Billion by 2030, rising at a CAGR of 8.17%. The market is growing due to increasing cancer prevalence, rising technological advancements in minimally invasive procedures, increasing investments in the field of interventional oncology, and the growing geriatric population in the country.
The rising prevalence of cancer in the U.S. is a major factor driving the market growth. According to the American Cancer Society, around. 2,041,910 new cancers are estimated to occur in the U.S. in 2025, while cancer is expected to cause 618,120 mortalities in the same year. As traditional treatments such as chemotherapy and radiation therapy often have significant side effects, minimally invasive alternatives such as radiofrequency ablation and microwave ablation are gaining popularity. These procedures offer localized tumor destruction with minimal damage to surrounding tissues, improving patient outcomes and driving demand for interventional oncology solutions.
Continuous technological advancements in interventional oncology are enhancing the effectiveness and adoption of these procedures. Companies operating in the market are focusing on innovation to introduce advanced products in the market, thereby improving patient outcomes. For instance, in September 2023, Profound Medical obtained 510(k) clearance from the U.S. FDA for its TULSA-PRO Thermal Boost module, which allows surgeons to temporarily elevate ablation temperatures in specific areas of the prostate. The Thermal Boost feature has led to improved treatment results in 88% of prostate cancer cases, thereby enhancing both efficacy and workflow efficiency. Such advancements improve clinical outcomes and increase the appeal of interventional oncology among healthcare providers.
The growing investment in interventional oncology from both public and private sectors is accelerating market expansion in the U.S. Government initiatives, research funding, and venture capital investments are supporting the development of innovative treatment modalities to improve precision oncology, ensuring that interventional techniques are integrated into mainstream cancer care. For instance, in December 2024, the Society of Interventional Radiology (SIR) Foundation awarded USD 1.5 million in grants to four research projects, two of which focus on interventional oncology. One study will develop a novel model of hepatocellular carcinoma (HCC), and the other will use genetic subtyping for precision-guided interventions for HCC.
This product will be delivered within 1-3 business days.
The rising prevalence of cancer in the U.S. is a major factor driving the market growth. According to the American Cancer Society, around. 2,041,910 new cancers are estimated to occur in the U.S. in 2025, while cancer is expected to cause 618,120 mortalities in the same year. As traditional treatments such as chemotherapy and radiation therapy often have significant side effects, minimally invasive alternatives such as radiofrequency ablation and microwave ablation are gaining popularity. These procedures offer localized tumor destruction with minimal damage to surrounding tissues, improving patient outcomes and driving demand for interventional oncology solutions.
Continuous technological advancements in interventional oncology are enhancing the effectiveness and adoption of these procedures. Companies operating in the market are focusing on innovation to introduce advanced products in the market, thereby improving patient outcomes. For instance, in September 2023, Profound Medical obtained 510(k) clearance from the U.S. FDA for its TULSA-PRO Thermal Boost module, which allows surgeons to temporarily elevate ablation temperatures in specific areas of the prostate. The Thermal Boost feature has led to improved treatment results in 88% of prostate cancer cases, thereby enhancing both efficacy and workflow efficiency. Such advancements improve clinical outcomes and increase the appeal of interventional oncology among healthcare providers.
The growing investment in interventional oncology from both public and private sectors is accelerating market expansion in the U.S. Government initiatives, research funding, and venture capital investments are supporting the development of innovative treatment modalities to improve precision oncology, ensuring that interventional techniques are integrated into mainstream cancer care. For instance, in December 2024, the Society of Interventional Radiology (SIR) Foundation awarded USD 1.5 million in grants to four research projects, two of which focus on interventional oncology. One study will develop a novel model of hepatocellular carcinoma (HCC), and the other will use genetic subtyping for precision-guided interventions for HCC.
U.S. Interventional Oncology Market Report: Segmentation
This report forecasts revenue growth at country levels and analyzes the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, the analyst has segmented the U.S. interventional oncology market report based on techniques, procedures, application, end use:Technique Outlook (Revenue, USD Million, 2018-2030)
- Ablation Therapies
- Embolization Therapies
- Biopsy Techniques
- Targeted Therapy Delivery Systems
- Image-Guided Procedures
Procedure Outlook (Revenue, USD Million, 2018-2030)
- Tumor Ablation
- Tumor Biopsy
- Vascular Interventions
- Palliative Care
Application Outlook (Revenue, USD Million, 2018-2030)
- Liver Cancer
- Lung Cancer
- Kidney Cancer
- Prostate Cancer
- Breast Cancer
- Other Cancer
End-use Outlook (Revenue, USD Million, 2018-2030)
- Hospitals
- Specialty Clinics
- Others
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Interventional Oncology Market Variables, Trends & Scope
Chapter 4. U.S. Interventional Oncology Market: Technique Estimates & Trend Analysis
Chapter 5. U.S. Interventional Oncology Market: Procedures Estimates & Trend Analysis
Chapter 6. U.S. Interventional Oncology Materials Market: Applications Estimates & Trend Analysis
Chapter 7. U.S. Interventional Oncology Market: End-use Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The companies profiled in this U.S. Interventional Oncology market report include:- Medtronic
- Boston Scientific Corporation
- Johnson & Johnson (Ethicon)
- Cook Medical
- AngioDynamics Inc.
- Stryker
- Terumo Corporation
- Siemens Healthineers (Varian)
- Teleflex Incorporated
- Profound Medical
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 125 |
| Published | April 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 998.4 Million |
| Forecasted Market Value ( USD | $ 1590 Million |
| Compound Annual Growth Rate | 8.1% |
| Regions Covered | United States |
| No. of Companies Mentioned | 11 |
